Predictive Oncology Management

Management criteria checks 3/4

Predictive Oncology's CEO is Raymond Vennare, appointed in Nov 2022, has a tenure of 1.67 years. total yearly compensation is $525.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $7.34K. The average tenure of the management team and the board of directors is 1.7 years and 3.4 years respectively.

Key information

Raymond Vennare

Chief executive officer

US$525.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	1.7yrs
CEO ownership	0.2%
Management average tenure	1.7yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

CEO Compensation Analysis

How has Raymond Vennare's remuneration changed compared to Predictive Oncology's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$525k	US$525k	-US$14m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$639k	US$88k	-US$26m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$33k	n/a	-US$20m

Compensation vs Market: Raymond's total compensation ($USD525.00K) is about average for companies of similar size in the US market ($USD697.54K).

Compensation vs Earnings: Raymond's compensation has been consistent with company performance over the past year.

CEO

Raymond Vennare (71 yo)

1.7yrs

Tenure

US$525,000

Compensation

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Raymond Vennare	CEO & Chairman	1.7yrs	US$525.00k	0.17% $ 7.3k
Joshua Blacher	Interim Chief Financial Officer	less than a year	no data	no data
Theresa Ferguson	Senior Director of Marketing	2.3yrs	no data	no data
Lawrence DeLucas	Senior Vice President of Biologics	no data	no data	no data
Arlette Uihlein	Senior VP of Translational Medicine & Drug Discovery and Medical Director	no data	no data	no data

1.7yrs

Average Tenure

Experienced Management: POAI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Raymond Vennare	CEO & Chairman	2.8yrs	US$525.00k	0.17% $ 7.3k
Bernard Harris	Member of Business Advisory Board	1.1yrs	no data	no data
Charles Nuzum	Lead Independent Director	4yrs	US$98.90k	no data
Andrew Einhorn	Member of Business Advisory Board	1.1yrs	no data	no data
Veena Rao-Mirmira	Independent Director	1.2yrs	US$73.34k	0.22% $ 9.4k
Marc Malandro	Member of Scientific Advisory Board	5.8yrs	no data	no data
Daniel Handley	Independent Director	4.4yrs	US$54.45k	0.45% $ 19.2k
Robert Murphy	Member of Scientific Advisory Board	5.8yrs	no data	no data
Matthew Hawryluk	Independent Director	1.7yrs	US$65.56k	0.23% $ 9.8k
Nancy Chung-Welch	Independent Director	4yrs	US$76.67k	0.52% $ 21.9k
Gregory St. Clair	Independent Director	4yrs	US$65.56k	0.55% $ 23.2k
Christoph Reinhard	Member of Scientific Advisory Board	1.3yrs	no data	no data

3.4yrs

Average Tenure

64yo

Average Age

Experienced Board: POAI's board of directors are considered experienced (3.4 years average tenure).

Predictive Oncology Management

Management criteria checks 3/4

Key information

Recent management updates

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

High number of new and inexperienced directors

Recent updates

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Share price stability

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.86 loss in 1Q 2023)

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Share price stability

New major risk - Market cap size

Full year 2023 earnings released: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$1.04 loss in 3Q 2022)

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$3.02 loss in 2Q 2022)

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

First quarter 2023 earnings released: US$0.86 loss per share (vs US$1.02 loss in 1Q 2022)

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Price target increased to US$5.00

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology has a new CEO

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Predictive Oncology announces retirement of CEO Mel Engle

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought US$62k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$4.50

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

CEO & Director Carl Schwartz has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

New 90-day high: US$1.40

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology regains Nasdaq compliance

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $3.074007 million.